Molecular tumor board–guided osimertinib therapy in EGFR L858R/Q701L–mutant lung adenocarcinoma supported by functional validation
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag242 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, online erschienen am 02.07.2026. Verfasst von Corinna Albers-Leischner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II (Oncology, Hematology, Bone Marrow Transplantation with Section Pneumology) and University Cancer Center (UCC) Hamburg, Uni…. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hamburg Cancer Society and the German Cancer Aid.
Abstract (Originalsprache)
Background
Rare or compound EGFR variants in non–small-cell lung cancer (NSCLC) can create substantial therapeutic uncertainty, particularly when accompanied by additional co-alterations with potential resistance implications. In such settings, molecular tumor boards (MTBs) may integrate genomic, functional, and clinical data to guide treatment selection. Case presentation A 59-year-old Caucasian woman was diagnosed with metastatic lung adenocarcinoma involving the lungs, bones, and lymph nodes. Histopathology showed a TTF-1 positive pulmonary adenocarcinoma with low PD-L1 expression. Molecular findings Next-generation sequencing identified a compound EGFR alteration consisting of L858R and Q701L, along with additional alterations in PIK3CA, ATM, and CTNNB1 and loss of CDKN2A/B, MLH1, and BAP1. Functional and molecular tumor board assessment To resolve this uncertainty, the EGFR mutations were recreated in vitro and characterized within national Network Genomic Medicine (nNGM) preclinical platform. In Ba/F3 models, the EGFR L858R/Q701L co-mutation showed sensitivity to first-, second-, and third-generation EGFR tyrosine kinase inhibitors. After integrating the molecular profile, functional data, and clinical context, the institutional MTB recommended in-label therapy with Osimertinib. Outcome Treatment resulted in rapid clinical improvement and a radiologically confirmed partial remission followed by durable disease control for 18 months. Disease progression occurred thereafter, and the patient died 23.4 months after initial diagnosis.
Conclusion
This case highlights the importance of functional validation and multidisciplinary tumor board discussion in interpreting complex genomic profiles and guiding personalized therapy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine II (Oncology, Hematology, Bone Marrow Transplantation with Section Pneumology) and University Cancer Center (UCC) Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
- Department of Internal Medicine II, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
- Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, and University Cancer Center Schleswig-Holstein, 23538 Lübeck, Germany.
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
- Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
ORCID-Profile: Corinna Albers-Leischner, Matthias Ritgen, Sivahari Prasad Gorantla, Melanie Janning, Sonja Loges, Maximilian Christopeit
Förderung
- Hamburg Cancer Society and the German Cancer Aid
Zitieren
APA
Albers-Leischner, C., Ritgen, M., Paulsen, F. O., Schmidt, B., von Bubnoff, N., Gorantla, S. P., Letsch, A., Janning, M., Loges, S., Bokemeyer, C., & Christopeit, M. (2026). Molecular tumor board–guided osimertinib therapy in EGFR L858R/Q701L–mutant lung adenocarcinoma supported by functional validation. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag242
Vancouver
Albers-Leischner C, Ritgen M, Paulsen FO, Schmidt B, von Bubnoff N, Gorantla SP, et al. Molecular tumor board–guided osimertinib therapy in EGFR L858R/Q701L–mutant lung adenocarcinoma supported by functional validation. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag242
BibTeX
@article{AlbersLeischner2026,
author = {Albers-Leischner, Corinna and Ritgen, Matthias and Paulsen, Finn-Ole and Schmidt, Benjamin and von Bubnoff, Nikolas and Gorantla, Sivahari Prasad and Letsch, Anne and Janning, Melanie and Loges, Sonja and Bokemeyer, Carsten and Christopeit, Maximilian},
title = {Molecular tumor board–guided osimertinib therapy in EGFR L858R/Q701L–mutant lung adenocarcinoma supported by functional validation},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag242}
}
EUVIMED